Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Depreciation and Depletion (2022 - 2025)

Historic Depreciation and Depletion for Barinthus Biotherapeutics (BRNS) over the last 4 years, with Q3 2025 value amounting to $100000.0.

  • Barinthus Biotherapeutics' Depreciation and Depletion fell 8571.43% to $100000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 1481.48%. This contributed to the annual value of $2.6 million for FY2024, which is 1304.35% up from last year.
  • As of Q3 2025, Barinthus Biotherapeutics' Depreciation and Depletion stood at $100000.0, which was down 8571.43% from $1.2 million recorded in Q2 2025.
  • Barinthus Biotherapeutics' Depreciation and Depletion's 5-year high stood at $1.2 million during Q1 2025, with a 5-year trough of $100000.0 in Q3 2025.
  • Its 4-year average for Depreciation and Depletion is $566666.7, with a median of $600000.0 in 2024.
  • As far as peak fluctuations go, Barinthus Biotherapeutics' Depreciation and Depletion soared by 15000.0% in 2023, and later crashed by 8571.43% in 2025.
  • Barinthus Biotherapeutics' Depreciation and Depletion (Quarter) stood at $300000.0 in 2022, then surged by 133.33% to $700000.0 in 2023, then decreased by 14.29% to $600000.0 in 2024, then plummeted by 83.33% to $100000.0 in 2025.
  • Its Depreciation and Depletion was $100000.0 in Q3 2025, compared to $1.2 million in Q2 2025 and $1.2 million in Q1 2025.